Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 607 followers
Latest posts
Last updated 3 days ago
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
3 days ago
More than 3 million cases of cUTIs are treated annually in the...
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
8 days ago
ATLAS phase II/III trial in VEXAS underway, advancing momelotinib’s broader development programme.
GSK enters agreement to acquire Nuvalent, Inc.
11 days ago
Acquisition expected to be accretive to sales & core operating profit in...
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
23 days ago
Pivotal B-Well data show a significant 19% functional cure in the overall...
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
25 days ago
GSK will present new data from its expanding oncology portfolio and pipeline...
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
about 1 month ago
First RSV vaccine approved for adults aged 18-59 years at increased risk...
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
about 1 month ago
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority...
GSK presents latest respiratory research to advance patient care at ATS 2026
about 1 month ago
Patient preference and adherence research highlight potential of long-acting dosing regimens to...
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
about 2 months ago
Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial...
GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH
about 2 months ago
Designations recognise potential for efimosfermin to address significant unmet medical need &amp...
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation
about 2 months ago
Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio...